Synosia Therapeutics ^None

Synosia Therapeutics is a company that focuses on developing and selling products for unmet medical needs in psychiatry and neurology. The company has six clinical-stage compounds in its pipeline that were acquired through partnerships with Novartis, Roche, and Syngenta. Two of these compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's disease.